Year-end Sale % OFF 
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized primarily by motor dysfunction. Transcranial magneto-acoustic stimulation (TMAS), an emerging non-invasive brain neuromodulation technology, is increasingly being applied in the treatment of brain diseases. However, the effects of TMAS on PD are unknown, which is not well studied. Here, we utilized TMAS on PD model mice induced by MPTP to investigate the underlying mechanism of therapy. Our study found that TMAS improved the behavioral performance of PD model mice, enhancing the motor function and motivation for movement. Besides, it inhibited the increased beta oscillations in the motor cortex, while also reducing gamma oscillations. Moreover, the abnormally exaggerated beta-broad gamma phase amplitude coupling (PAC) was decreased after TMAS, and there was a significant negative correlation between PAC and both distance traveled and mean speed during the open filed test. Additionally, the ongoing stimulation could provide neuroprotection, implying that TMAS could ameliorate the loss of dopaminergic neurons, with no damage observed in the brain tissue of mice. Our findings suggest that TMAS could provide a non-invasive tool for the treatment of Parkinson's disease and beta-broad gamma phase amplitude coupling could be employed as a biomarker for PD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
